JP2015517484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517484A5 JP2015517484A5 JP2015510875A JP2015510875A JP2015517484A5 JP 2015517484 A5 JP2015517484 A5 JP 2015517484A5 JP 2015510875 A JP2015510875 A JP 2015510875A JP 2015510875 A JP2015510875 A JP 2015510875A JP 2015517484 A5 JP2015517484 A5 JP 2015517484A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- sequence
- peptide
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 4
- QDYOZKNUWCMVJZ-UWTATZPHSA-N (1R)-1-amino-2-sulfanylethanesulfinic acid Chemical group SC[C@H](N)S(O)=O QDYOZKNUWCMVJZ-UWTATZPHSA-N 0.000 claims 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N 3-Mercaptopropane-1,2-diol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000003840 hydrochlorides Chemical class 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 229940035024 thioglycerol Drugs 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003449 preventive Effects 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Claims (13)
・トレハロース又はショ糖の少なくとも１種
を更に含む請求項７記載の医薬組成物。 The pharmaceutical composition according to claim 7, further comprising at least one of thioglycerol, thioanisole or methionine; and / or at least one of trehalose or sucrose.
・SEQ ID NO: 2から7の配列から成る6種のペプチドの酢酸塩；
・トレハロース；
・チオグリセロール；
・メチオニン及び任意成分として、
・リン酸
を含む請求項７又は８記載の医薬組成物。 The hydrochloride salt of the peptide consisting of the sequence SEQ ID NO: 1;
SEQ ID NO: 6 peptide acetates consisting of sequences 2 to 7;
・ Trehalose;
Thioglycerol;
・ As methionine and optional ingredients
-Pharmaceutical composition of Claim 7 or 8 containing phosphoric acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201208293A GB201208293D0 (en) | 2012-05-11 | 2012-05-11 | Hydrochlorice salt of peptide |
| GB1208293.9 | 2012-05-11 | ||
| PCT/GB2013/051201 WO2013167897A1 (en) | 2012-05-11 | 2013-05-09 | Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517484A JP2015517484A (en) | 2015-06-22 |
| JP2015517484A5 true JP2015517484A5 (en) | 2016-06-30 |
| JP5982562B2 JP5982562B2 (en) | 2016-08-31 |
Family
ID=46396890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510875A Expired - Fee Related JP5982562B2 (en) | 2012-05-11 | 2013-05-09 | Peptide hydrochloride and its immunotherapy use in combination with other peptides |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9657061B2 (en) |
| EP (1) | EP2847209B8 (en) |
| JP (1) | JP5982562B2 (en) |
| KR (1) | KR20150014955A (en) |
| CN (1) | CN104428311B (en) |
| AU (1) | AU2013257784A1 (en) |
| BR (1) | BR112014028130A2 (en) |
| CA (1) | CA2873120A1 (en) |
| EA (1) | EA201492068A1 (en) |
| GB (2) | GB201208293D0 (en) |
| HK (1) | HK1201850A1 (en) |
| IL (1) | IL235388A (en) |
| IN (1) | IN2014DN09367A (en) |
| MX (1) | MX2014013394A (en) |
| SG (1) | SG11201407446TA (en) |
| WO (1) | WO2013167897A1 (en) |
| ZA (1) | ZA201408290B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| DK3236985T4 (en) | 2014-12-23 | 2022-11-28 | Immatics Biotechnologies Gmbh | PREVIOUSLY UNKNOWN PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCER |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| TWI792442B (en) * | 2021-07-23 | 2023-02-11 | 建誼生技股份有限公司 | Method for preparing etelcalcetide hydrochloride |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE414534T1 (en) * | 2001-12-05 | 2008-12-15 | Circassia Ltd | IMMUNOTHERAPEUTIC METHODS AND SYSTEMS |
| KR101728868B1 (en) * | 2006-01-18 | 2017-05-02 | 포시 파마슈티컬스 컴퍼니 리미티드 | Pharmaceutical compositions with enhanced stability |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| PT2083856E (en) * | 2007-08-15 | 2010-12-23 | Circassia Ltd | Peptides for desensibilization against allergens |
| GB2455108A (en) * | 2007-11-28 | 2009-06-03 | Circassia Ltd | T-Cell dependent method for detecting non-allergic or intrinsic disorders |
| GB0821806D0 (en) * | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| HUE033656T2 (en) * | 2010-03-31 | 2017-12-28 | Stabilitech Ltd | Excipients for stabilising viral particles |
-
2012
- 2012-05-11 GB GB201208293A patent/GB201208293D0/en not_active Ceased
-
2013
- 2013-05-09 IN IN9367DEN2014 patent/IN2014DN09367A/en unknown
- 2013-05-09 KR KR20147034734A patent/KR20150014955A/en not_active Application Discontinuation
- 2013-05-09 CA CA 2873120 patent/CA2873120A1/en not_active Abandoned
- 2013-05-09 WO PCT/GB2013/051201 patent/WO2013167897A1/en active Application Filing
- 2013-05-09 JP JP2015510875A patent/JP5982562B2/en not_active Expired - Fee Related
- 2013-05-09 BR BR112014028130A patent/BR112014028130A2/en not_active IP Right Cessation
- 2013-05-09 EP EP13722023.2A patent/EP2847209B8/en active Active
- 2013-05-09 SG SG11201407446TA patent/SG11201407446TA/en unknown
- 2013-05-09 GB GB201421491A patent/GB2517354A/en not_active Withdrawn
- 2013-05-09 EA EA201492068A patent/EA201492068A1/en unknown
- 2013-05-09 US US14/400,052 patent/US9657061B2/en active Active - Reinstated
- 2013-05-09 CN CN201380036507.6A patent/CN104428311B/en not_active Expired - Fee Related
- 2013-05-09 AU AU2013257784A patent/AU2013257784A1/en not_active Abandoned
- 2013-05-09 MX MX2014013394A patent/MX2014013394A/en unknown
-
2014
- 2014-10-29 IL IL235388A patent/IL235388A/en not_active IP Right Cessation
- 2014-11-12 ZA ZA2014/08290A patent/ZA201408290B/en unknown
-
2015
- 2015-03-05 HK HK15102275.5A patent/HK1201850A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517484A5 (en) | ||
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| NZ759512A (en) | Delayed release compositions of linaclotide | |
| JP2015078230A5 (en) | ||
| PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
| JP2016532722A5 (en) | ||
| PH12018501236A1 (en) | Pharmaceutical composition comprising a potent inhibitor urat1 | |
| WO2014096985A3 (en) | A stable aqueous composition comprising human insulin or an analogue or derivative thereof | |
| JP2015513318A5 (en) | ||
| WO2015114395A9 (en) | Process for the preparation of vortioxetine salts | |
| EA201391018A1 (en) | PREPARATIONS OF IMMUNOSUPRESSANTS | |
| JP2020513418A5 (en) | ||
| JP2018529626A5 (en) | ||
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| WO2015024022A3 (en) | Designed peptides for tight junction barrier modulation | |
| WO2013021284A3 (en) | Anti-il-6 vaccine composition | |
| CL2022001317A1 (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor | |
| JP2013542196A5 (en) | ||
| WO2012162637A3 (en) | Vaccine adjuvants from self-assembling peptides | |
| MX2013003551A (en) | Solid state forms of a potent hcv inhibitor. | |
| HRP20140819T1 (en) | Compositions and methods for preventing or treating aids | |
| JP2016160183A5 (en) | Muscle atrophy inhibitor and food and drink for muscle atrophy suppression | |
| WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
| EA032385B9 (en) | Pharmaceutical composition for treating gastrointestinal diseases |